Ubrogepant vs. Triptans: Superior Relief for Migraines

Research Summary

A recent study published in Pain Management highlights the benefits of switching from triptans to ubrogepant for acute migraine treatment. The UNIVERSE II study surveyed Migraine Buddy app users who transitioned from one oral triptan to another or to ubrogepant over four weeks. The study involved 211 participants and revealed that those switching to ubrogepant reported significantly higher satisfaction in treating migraine pain and alleviating bothersome symptoms compared to those switching triptans. At Day 30, 69.4% of the ubrogepant group were satisfied versus 42.0% in the triptan group. Additionally, 75.7% of ubrogepant users preferred their new treatment, experiencing meaningful relief within two hours.

Study Details

📄 Title: Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

👥 Research Team: Lipton RB et al.

📚 Published In: Pain Manag

📅 Publication Date: 2025 Nov 19

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.